205 related articles for article (PubMed ID: 17571283)
41. Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats.
Kim K; Yoon I; Chun I; Lee N; Kim T; Gwak HS
Drug Deliv; 2011 Jan; 18(1):79-83. PubMed ID: 20809680
[TBL] [Abstract][Full Text] [Related]
42. Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans.
Sun JX; Niecestro R; Phillips G; Shen J; Lukacsko P; Friedhoff L
J Clin Pharmacol; 2002 Feb; 42(2):198-204. PubMed ID: 11831543
[TBL] [Abstract][Full Text] [Related]
43. Novel extended-release formulation of lovastatin by one-step melt granulation: in vitro and in vivo evaluation.
Ochoa L; Igartua M; Hernández RM; Gascón AR; Solinis MA; Pedraz JL
Eur J Pharm Biopharm; 2011 Feb; 77(2):306-12. PubMed ID: 21172434
[TBL] [Abstract][Full Text] [Related]
44. Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Kosoglou T; Zhu Y; Statkevich P; Triantafyllou I; Taggart W; Xuan F; Kim KT; Cutler DL
Eur J Clin Pharmacol; 2011 May; 67(5):483-92. PubMed ID: 21120461
[TBL] [Abstract][Full Text] [Related]
45. Gender differences in pharmacokinetics of a combination tablet of niacin extended-release/simvastatin in healthy Chinese volunteers.
Wang XL; Liu M; Yang M; Zhang YN; Zhang D; Zhang LN; Han J; Liu HC
Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):321-6. PubMed ID: 24346851
[TBL] [Abstract][Full Text] [Related]
46. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
Gupta EK; Ito MK
Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
[TBL] [Abstract][Full Text] [Related]
47. Bioavailability of alendronate and vitamin D(3) in an alendronate/vitamin D(3) combination tablet.
Denker AE; Lazarus N; Porras A; Ramakrishnan R; Constanzer M; Scott BB; Chavez-Eng C; Woolf E; Maganti L; Larson P; Gottesdiener K; Wagner JA
J Clin Pharmacol; 2011 Oct; 51(10):1439-48. PubMed ID: 21148044
[TBL] [Abstract][Full Text] [Related]
48. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
[TBL] [Abstract][Full Text] [Related]
49. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets.
Fiske WD; Jobes J; Xiang Q; Chang SC; Benedek IH
J Pain; 2012 Jan; 13(1):90-9. PubMed ID: 22208805
[TBL] [Abstract][Full Text] [Related]
50. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
[TBL] [Abstract][Full Text] [Related]
51. Pharmacological doses of nicotinic acid and nicotinamide are independently metabolized in rats.
Shibata K; Fukuwatari T; Suzuki C
J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):86-93. PubMed ID: 24975217
[TBL] [Abstract][Full Text] [Related]
52. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
Moon YS; Kashyap ML
Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
[TBL] [Abstract][Full Text] [Related]
53. Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine.
Siegmund W; Siegert J; Richter K; Schnabel F; Feustel C; Kirch W
J Clin Pharmacol; 2012 May; 52(5):681-90. PubMed ID: 21551317
[TBL] [Abstract][Full Text] [Related]
54. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
[TBL] [Abstract][Full Text] [Related]
55. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
[TBL] [Abstract][Full Text] [Related]
56. Advicor (niacin extended-release and lovastatin tablets).
Scarpa WJ
J Clin Hypertens (Greenwich); 2002; 4(2):146. PubMed ID: 11927800
[No Abstract] [Full Text] [Related]
57. Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers.
Timmer CJ; Sitsen JM
J Pharm Sci; 2003 Sep; 92(9):1773-8. PubMed ID: 12949996
[TBL] [Abstract][Full Text] [Related]
58. [Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets].
Xiong HR; Tan QY; Liu BL; Luo W; Zhang JQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 42(5):657-60. PubMed ID: 22007493
[TBL] [Abstract][Full Text] [Related]
59. Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study.
Akhter KP; Ahmad M; Khan SA; Ramzan M; Shafi I; Muryam B; Javed Z; Murtaza G
Acta Pol Pharm; 2012; 69(1):81-5. PubMed ID: 22574510
[TBL] [Abstract][Full Text] [Related]
60. Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects.
Cleary JD; Evans PC; Hikal AH; Chapman SW
Am J Health Syst Pharm; 1999 Aug; 56(15):1529-34. PubMed ID: 10478991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
